In what might come as a relief for many patients who suffer from disability due to multiple sclerosis (a neurological disorder in younger persons), clinical trials for a medicine to treat this disease has been approved.
The move is despite stringent regulations recently introduced by the Drug Controller General of India which had halted clinical trials in the country for a while.PGIMER is one of seven such institutes in India which has been selected for the trials to be conducted in 32 countries.
The drug `ofatumumab' for which the trial will start soon is expected to offer lesser side effects and will be more effective than the existing drug `teriflunomide' in patients who suffer from relapsing multiple sclerosis. In India, some 9-10 in every 1 lakh persons suffer from the disease. It is believed that there are over 1 lakh patients in the country .
Usually patients show recurring and recovering pattern of neurological symptoms (also called relapsing and remitting). The common symptoms include visual problems, overwhelming fatigue, difficulty in maintaining balance and coordination, various levels of impaired mobility , muscle weakness and stiffness.
The drug `ofatumumab' for which the trial will start soon is expected to offer lesser side effects and will be more effective than the existing drug `teriflunomide' in patients who suffer from relapsing multiple sclerosis. In India, some 9-10 in every 1 lakh persons suffer from the disease. It is believed that there are over 1 lakh patients in the country .
Usually patients show recurring and recovering pattern of neurological symptoms (also called relapsing and remitting). The common symptoms include visual problems, overwhelming fatigue, difficulty in maintaining balance and coordination, various levels of impaired mobility , muscle weakness and stiffness.
ᐧ
Comments